Clinical implications of the intrinsic molecular subtypes of breast cancer

Breast

Volumn 24, Issue , 2015, Pages S26-S35

  Prat, Aleix ^a,b,c   Pineda, Estela ^a,b   Adamo, Barbara ^a,b   Galván, Patricia ^a,c   Fernández, Aranzazu ^a,b   Gaba, Lydia ^a,b   Díez, Marc ^a,b   Viladot, Margarita ^a,b   Arance, Ana ^a,b   Muñoz, Montserrat ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Breast cancer; Gene expression; PAM50; Subtype

Indexed keywords

ANTIANDROGEN; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; INTERMETHOD COMPARISON; LUMINAL A BREAST CANCER; METASTASIS; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SYNDROME DELINEATION; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMISTRY; CLASSIFICATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; NEOADJUVANT THERAPY; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84948709397     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.07.008     Document Type: Article

References (93)

1. La Vecchia C., Bosetti C., Lucchini F., Bertuccio P., Negri E., Boyle P., et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010, 21:1323-1360.
2. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
3. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5-23.
4. Prat A., Parker J.S., Fan C., Perou C.M. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012, 135:301-306.
5. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
6. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
7. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
8. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013, 24:2206-2223.
9. Maisonneuve P., Disalvatore D., Rotmensz N., Curigliano G., Colleoni M., Dellapasqua S., et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014, 16:R65.
10. Prat A., Cheang M.C., Martin M., Parker J.S., Carrasco E., Caballero R., et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013, 31:203-209.
11. Cheang M.C.U., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 Index, HER2 status, and prognosis of patients with luminal B breast Cancer. J Natl Cancer Inst 2009, 101:736-750.
12. Prat A., Lluch A., Albanell J., Barry W.T., Fan C., Chacon J.I., et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 2014, 111:1532-1541.
13. Sikov W., Barry W., Hoadley K., Pitcher B., Singh B., Tolaney S., et al. Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT)+/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance). San Ant Breast Cancer Symp 2014, 2012:S4-S05.
14. Bastien R.R., Rodriguez-Lescure A., Ebbert M.T., Prat A., Munarriz B., Rowe L., et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012, 5:44.
15. Prat A., Adamo B., Cheang M.C., Anders C.K., Carey L.A., Perou C.M. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013, 18:123-133.
16. Dunbier A.K., Anderson H., Ghazoui Z., Salter J., Parker J.S., Perou C.M., et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids 2011, 76:736-740.
17. Chia S.K., Bramwell V.H., Tu D., Shepherd L.E., Jiang S., Vickery T., et al. A 50-Gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012, 18:4465-4472.
18. Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011, 29:2342-2349.
19. Dowsett M., Sestak I., Lopez-Knowles E., Sidhu K., Dunbier A.K., Cowens J.W., et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013, 31:2783-2790.
20. Gnant M., Filipits M., Greil R., Stoeger H., Rudas M., Bago-Horvath Z., et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014, 25:339-345.
21. Martín M., González-Rivera M., Morales S., de la Haba J., González-Cortijo L., Manso L., et al. Prospective study of the impact of the Prosigna™ assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: a GEICAM study. San Ant Breast Cancer Symp 2014, 2012. P6-08-10.
22. Nielsen T.O., Parker J.S., Leung S., Voduc D., Ebbert M., Vickery T., et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:5222-5232.
23. Prat A., Carey L.A., Adamo B., Vidal M., Tabernero J., Cortés J., et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014, 106.
24. Curtis C., Shah S.P., Chin S.-F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
25. Prat A., Bianchini G., Thomas M., Belousov A., Cheang M.C., Koehler A., et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014, 20:511-521.
26. Carey L., Berry D., Ollila D., Harris L., Krop I., Weckstein D., et al. Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. Proc Am Soc Clin Oncol 2013, a500.
27. Prat A., Ellis M.J., Perou C.M. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2012, 9:48-57.
28. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011 Nov 16, 103(22):1656-1664.
29. Hammond M.E.H., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
30. Wolff A.C., Hammond M.E.H., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013, 31:3997-4013.
31. McCullough A., Dell'Orto P., Reinholz M., Gelber R., Dueck A., Russo L., et al. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat 2014, 143:485-492.
32. Prat A., Cheang M.C.U., Martín M., Parker J.S., Carrasco E., Caballero R., et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013, 31:203-209.
33. Roberts S.A., Lawrence M.S., Klimczak L.J., Grimm S.A., Fargo D., Stojanov P., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013, 45:970-976.
34. Kuong K.J., Loeb L.A. APOBEC3B mutagenesis in cancer. Nat Genet 2013, 45:964-965.
35. Prat A., Cruz C., Hoadley K., Díez O., Perou C., Balmaña J. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Res Treat 2014, 147:185-191.
36. Foulkes W.D., Stefansson I.M., Chappuis P.O., Bégin L.R., Goffin J.R., Wong N., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast Cancer. J Natl Cancer Inst 2003, 95:1482-1485.
37. Schneider B.P., Winer E.P., Foulkes W.D., Garber J., Perou C.M., Richardson A., et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14:8010-8018.
38. Prat A., Adamo B., Fan C., Peg V., Vidal M., Galvan P., et al. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013, 3:3544.
39. Hoadley K.A., Yau C., Wolf D.M., Cherniack A.D., Tamborero D., Ng S., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014, 158:929-944.
40. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913.
41. Molyneux G., Geyer F.C., Magnay F.-A., McCarthy A., Kendrick H., Natrajan R., et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417.
42. Keller P.J., Arendt L.M., Skibinski A., Logvinenko T., Klebba I., Dong S., et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci 2012, 109:2772-2777.
43. Anderson W.F., Rosenberg P.S., Prat A., Perou C.M., Sherman M.E. How many etiological subtypes of breast cancer: two, three, four, or more?. J Natl Cancer Inst 2014, 106.
44. Millikan R., Newman B., Tse C.-K., Moorman P., Conway K., Smith L., et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139.
45. Liu M., Pitcher B., Mardis E., Davies S., Snider J., Vickery T., et al. PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy. San Ant Breast Cancer Symp 2012, 2012. P2-10-01.
46. Martín M., Prat A., Rodríguez-Lescure Á., Caballero R., Ebbert M.W., Munárriz B., et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat 2013, 138:457-466.
47. Cheang M.C., Voduc K.D., Tu D., Jiang S., Leung S., Chia S.K., et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012, 18:2402-2412.
48. Filipits M., Nielsen T.O., Rudas M., Greil R., Stöger H., Jakesz R., et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014 Mar 1, 20(5):1298-1305.
49. Sestak I., Cuzick J., Dowsett M., Lopez-Knowles E., Filipits M., Dubsky P., et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 2015, 33:916-922.
50. Sestak I., Dowsett M., Zabaglo L., Lopez-Knowles E., Ferree S., Cowens J.W., et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 2013 Oct 2, 105(19):1504-1511.
51. Usary J., Zhao W., Darr D., Roberts P.J., Liu M., Balletta L., et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 2013, 19:4889-4899.
52. von Minckwitz G., Blohmer J.U., Costa S.D., Denkert C., Eidtmann H., Eiermann W., et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013 Oct 10, 31(29):3623-3630.
53. von Minckwitz G., Untch M., Blohmer J.-U., Costa S.D., Eidtmann H., Fasching P.A., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804.
54. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
55. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164-172.
56. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
57. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65.
58. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444. Early Breast Cancer Trialists' Collaborative G.
59. Coates A.S., Colleoni M., Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal A breast cancer?. J Clin Oncol 2012, 30:1260-1263.
60. Hayes D.F. Targeting adjuvant chemotherapy: a good idea that needs to be proven!. J Clin Oncol 2012, 30:1264-1267.
61. Mackey J.R., Martin M., Pienkowski T., Rolski J., Guastalla J.-P., Sami A., et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013, 14:72-80.
62. Ellis M.J., Tao Y., Luo J., A'Hern R., Evans D.B., Bhatnagar A.S., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100:1380-1388.
63. Hugh J., Hanson J., Cheang M.C.U., Nielsen T.O., Perou C.M., Dumontet C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176.
64. Iwamoto T., Booser D., Valero V., Murray J.L., Koenig K., Esteva F.J., et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012, 30:729-734.
65. Cheang M., Martin M., Nielsen T., Prat A., Rodriguez-Lescure A., Ruiz A., et al. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. Proc Am Soc Clin Oncol 2012, a1008.
66. Prat A., Parker J.S., Fan C., Cheang M.C.U., Miller L.D., Bergh J., et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012, 23:2866-2873.
67. Vaz-Luis I., Ottesen R., Hughes M., Marcom P.K., Moy B., Rugo H., et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 2012, 14:R129.
68. Perez E.A., Romond E.H., Suman V.J., Jeong J.-H., Davidson N.E., Geyer C.E., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29:3366-3373.
69. de Azambuja E., Holmes A.P., Piccart-Gebhart M., Holmes E., Di Cosimo S., Swaby R.F., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014, 15:1137-1146.
70. Piccart-Gebhart M., Holmes A., Baselga J., De Azambuja D., Dueck A., Viale G., et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Proc Am Soc Clin Oncol 2014, LBA4.
71. Tolaney S.M., Barry W.T., Dang C.T., Yardley D.A., Moy B., Marcom P.K., et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015, 372:134-141.
72. Eiermann W, Baselga J, Semiglazov V, Byakhov M, Ciruelos E, Ojeda B, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384.
73. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
74. Eiermann W., Baselga J., Semiglazov V., Byakhov M., Ciruelos E., Ojeda B., et al. Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC). EBCC-6, European breast cancer conference, Poster: 228 2008.
75. Gianni L., Eiermann W., Semiglazov V., Lluch A., Tjulandin S., Zambetti M., et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014, 15:640-647.
76. Untch M., Gelber R.D., Jackisch C., Procter M., Baselga J., Bell R., et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008, 19:1090-1096.
77. Perez E.A., Romond E.H., Suman V.J., Jeong J.-H., Sledge G., Geyer C.E., et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014, 32:3744-3752.
78. Pogue-Geile K.L., Song N., Jeong J.-H., Gavin P.G., Kim S.-R., Blackmon N.L., et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015 Apr 20, 33(12):1340-1347.
79. Gianni L., Pienkowski T., Im Y.-H., Roman L., Tseng L.-M., Liu M.-C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
80. Rimawi M.F., Mayer I.A., Forero A., Nanda R., Goetz M.P., Rodriguez A.A., et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013, 31:1726-1731.
81. Prat A., Baselga J. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. J Clin Oncol 2013, 31:1703-1706.
82. Rimawi M., Niravath P., Wang T., Rexer B., Forero A., Wolff A., et al. TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer. San Ant Breast Cancer Symp 2014, 2012. S6-02.
83. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
84. Lehmann B.D., Pietenpol J.A. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014, 232:142-150.
85. Burstein M.D., Tsimelzon A., Poage G.M., Covington K.R., Contreras A., Fuqua S., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015 Apr 1, 21(7):1688-1698.
86. Masuda H., Baggerly K.A., Wang Y., Zhang Y., Gonzalez-Angulo A.M., Meric-Bernstam F., et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013, 19:5533-5540.
87. Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014, 25:1544-1550.
88. Ali H.R., Provenzano E., Dawson S.-J., Blows F.M., Liu B., Shah M., et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol 2014, 25:1536-1543.
89. Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
90. Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2014.
91. von Minckwitz G., Schneeweiss A., Loibl S., Salat C., Denkert C., Rezai M., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014, 15:747-756.
92. Tutt A., Ellis P., Kilburn L., Gilett C., Pinder S., Abraham J., et al. The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). San Ant Breast Cancer Symp 2014, 2012. S3-01.
93. Gucalp A., Tolaney S., Isakoff S.J., Ingle J.N., Liu M.C., Carey L.A., et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013, 19:5505-5512.